Technical Analysis for PTCT - PTC Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 43.635 2.14% 0.92
PTCT closed down 0.65 percent on Thursday, November 14, 2019, on 69 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical PTCT trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 2.14%
Overbought Stochastic Strength 2.14%
Stochastic Reached Overbought Strength 1.48%
Overbought Stochastic Strength 1.48%
Up 3 Days in a Row Strength 1.48%
Up 4 Days in a Row Strength 1.48%
Up 3 Days in a Row Strength 4.46%
Pocket Pivot Bullish Swing Setup 5.65%
Upper Bollinger Band Touch Strength 5.65%
1,2,3 Pullback Bullish Bullish Swing Setup 5.96%

Older signals for PTCT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases New Jersey Gene Expression Neurological Disorders Astrazeneca Muscular Dystrophy Celgene Spinal Muscular Atrophy Dystrophy Neurodegenerative Disorders Neuromuscular Disorders
Is PTCT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 48.81
52 Week Low 27.53
Average Volume 772,807
200-Day Moving Average 39.3581
50-Day Moving Average 38.5285
20-Day Moving Average 39.9085
10-Day Moving Average 41.226
Average True Range 1.3839
ADX 37.15
+DI 32.5646
-DI 10.2721
Chandelier Exit (Long, 3 ATRs ) 38.9983
Chandelier Exit (Short, 3 ATRs ) 39.7117
Upper Bollinger Band 43.6015
Lower Bollinger Band 36.2155
Percent B (%b) 0.88
BandWidth 18.507336
MACD Line 1.2171
MACD Signal Line 0.8877
MACD Histogram 0.3293
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 41.4 Million
EPS -3.05
Price-to-Earnings (P/E) Ratio -14.01
Price-to-Sales 5.48
Price-to-Book 3.95
PEG Ratio 0.73
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.47
Resistance 3 (R3) 44.40 43.74 44.18
Resistance 2 (R2) 43.74 43.29 43.78 44.08
Resistance 1 (R1) 43.23 43.02 42.90 43.30 43.98
Pivot Point 42.58 42.58 42.41 42.61 42.58
Support 1 (S1) 42.07 42.13 41.74 42.14 41.46
Support 2 (S2) 41.41 41.86 41.45 41.36
Support 3 (S3) 40.90 41.41 41.26
Support 4 (S4) 40.97